Record revenue, flat profit—the ESOP mask and the Plant 6 pivot
Windlas reported its highest-ever quarterly revenue at ₹248.1 Cr with 18% YoY growth, but actual profit flat-lined at ₹17.7 Cr. Management's 37% PAT growth claim rests entirely on a ₹7.2 Cr ESOP adjustment. The real story: operational leverage has stalled, Trade Generics is broken, and the entire margin recovery thesis now hinges on Plant 6 commercialization in H1 FY27.
₹17.7 Cr
−0.1% YoY (flat)
₹25 Cr
+37% YoY (ESOP-adjusted)
₹7.2 Cr
non-cash charge
₹248.1 Cr
+18.1% YoY
On the result screen, Windlas printed its record-highest quarterly revenue at ₹248.1 Cr and celebrated 14 consecutive quarters of revenue records. Yet profit didn't move. Management's earnings-call claim of 37% PAT growth hinges entirely on removing a ₹7.2 Cr non-cash ESOP charge—a framing that masks a hard truth: the company added ₹49 Cr in topline volume but captured zero additional profit. At ₹17.7 Cr actual PAT, growth was flat YoY. That is the quarter's defining tension.
Why profit failed to expand despite 18% revenue growth
Operating margins—both OPM (10.8%) and NPM (7.0%)—held flat despite the 18% revenue lift. The revenue mix shifted sharply: CDMO (the highest-margin vertical) surged 29% to ₹207 Cr, but this gain was entirely offset by the 65% collapse in Trade Generics + Institutional, which fell from ~₹85–90 Cr annually to a ₹30 Cr run rate following the codeine product discontinuation. Exports grew 79% but from a small ₹11 Cr base (4% of total). The math is brutal: high-margin volume (CDMO) was forced to subsidize the fixed-cost base that codeine once covered. Employee costs rose 17% ex-ESOP—partly reflecting volume-driven manpower additions, but also structural pressure from Uttarakhand minimum wage increases (retrospective) and contractual variable labor tied to production. No pricing power materialized; cost-plus customer contracts provided no buffer.
37% PAT growth to ₹25 Cr
₹17.7 Cr actual PAT, flat YoY (−0.1%)
Overstated. ESOP-adjusted claim obscures zero operating leverage.
Record-highest quarterly revenue of ₹248 Cr
Delivered ₹248.1 Cr, 18.1% YoY growth
Supported. Precise match; 14-quarter streak confirmed.
CDMO 29% YoY growth, highest in long time
CDMO ₹207 Cr, +29% YoY
Supported. But management cautioned: not necessarily repeatable. 'Business as usual.'
Plant 6 on track for H1 FY27 commercialization
Mechanical completion done; validations and customer audits ongoing
Supported. Targeting end of H1 (Sep 2026 ±15 days).
TGx momentum hit but temporary
TGx fell from ₹85–90 Cr annually to ₹30–35 Cr run rate; flat ex-codeine for 3–4 quarters
Partially supported. 'Temporary' is unproven; recovery mechanism (new launches, geography) early-stage.
What changed on this call
Four segments shifted materially, each signalling where the business is rebalancing.
CDMO surge to 29% (₹207 Cr). Driven by customer expansion, deeper engagement, new product launches. Highest in years. Management deflected sustainability questions; attributed growth to 'business as usual,' not external tailwind. Risk: base effect risk if quarterly conversion rates revert.
Trade Generics collapse and stagnation (₹30 Cr, down from ₹85–90 Cr annually). Codeine-based products discontinued; management working on new launches, geographic expansion, portfolio depth (150–200+ SKUs). Recovery timeline vague. Management calls it 'a temporary hit for a few quarters,' but analysts pressed hard; three to four quarters flat ex-codeine base suggests structural, not cyclical, pressure.
Exports 79% growth (₹11 Cr, small base). Geography expansion, portfolio, plant approvals ongoing. High gestation period (12–18 months per call). Management optimistic long-term but cautious on near-term scale. Early-stage catalyst.
Injectables back on track after slower start. Infrastructure (2 lines + supportive facilities) in place. No new capex announced; capacity addition 6–8 months if management decides. Customer feedback positive; inquiries flowing. Small contributor currently but positioned as future growth vector.
The bull-bear ledger
14 consecutive quarters of record revenue. Execution track record is real.
CDMO 29% growth; largest vertical (83% of revenue) is scaling.
Plant 6 on schedule (mechanical completion done). Concrete catalyst for H1 FY27.
Strong balance sheet and cash generation (₹47 Cr buyback + ₹13 Cr dividend FY26). Fortress balance sheet, per analysts.
Exports accelerating at 79%. New geographic markets and product registrations could be multi-year tailwind.
Reported PAT flat YoY despite 18% revenue growth. No operating leverage materializing.
Trade Generics stagnant even ex-codeine base for 3–4 quarters. Recovery unproven and timeline vague.
ESOP-adjusted profit claims obscure actual earnings quality. 37% growth claim vs. flat actual profit erodes credibility.
Plant 6 depreciation drag: ~₹3 Cr/quarter initially. Short-term margin headwind as plant ramps.
API price volatility persists. Geopolitical factors (Middle East) unpredictable. Inventory buildup required; working capital stretched during quarter.
CDMO growth sustainability unclear. Management explicitly cautioned against extrapolation; growth attributed to conversion timing, not structural tailwind.
Ranked risks—what should concern a holder
Trade Generics stagnation persists longer than expected
HighTGx fell from ₹85–90 Cr annually to ₹30–35 Cr. Even ex-codeine base, flat for 3–4 quarters. Recovery via new launches and geography is early-stage; management timeline vague. If stagnation extends into FY27, margin recovery from Plant 6 could be offset by TGx drag.
Flat PAT despite 18% revenue growth signals zero operating leverage
HighOPM and NPM both flat YoY. No pricing power, no cost absorption. Fixed costs (infrastructure, overhead) are delevering. If CDMO growth slows or margins compress, profit could decline absolutely despite topline growth.
Plant 6 execution and ramp risk
MediumMechanical completion done, but validations and customer audits still ongoing. Depreciation drag (~₹3 Cr/quarter) starts Q2–Q3. Customer adoption may lag initial expectations. If ramp slower than modeled, near-term PAT could face additional margin pressure.
CDMO 29% growth sustainability unclear
MediumManagement explicitly cautioned: 'Do not read too much into a single quarter.' Growth attributed to 'business as usual' execution and conversion timing, not external tailwind. If quarterly conversion reverts to historical 17–20% growth, topline guidance and market expectations could disappoint.
API price volatility; geopolitical factors uncontrollable
MediumCost-plus pricing provides some pass-through, but lag and negotiation complexity remain. Inventory buildup and receivables stretches during volatile periods create working capital drag. Middle East crisis (noted impact) is beyond company control.
Earnings quality concerns; ESOP-adjusted profit messaging
Medium37% PAT growth claim (ESOP-adjusted, ₹25 Cr) vs. actual flat PAT (₹17.7 Cr) raises red flags on management credibility. Non-GAAP metrics obscure operational reality. Analyst pushback was notable; market may demand clearer guidance.
The debate: can margin expand from Plant 6 before TGx drag persists?
How the street is positioned
The market accepted the quarter with conviction. The day-1 pop of +12.32% held and expanded to +13.08% by day 3 post-announcement, signalling broad-based relief rather than short-term momentum-chasing. As of 2026-08-14, the stock trades at ₹949.45—above its SMA20 (₹877.2), SMA50 (₹854.68), and SMA200 (₹817.72), confirming an intact uptrend. At ₹949.45, it sits only −3.71% from its all-time high (₹986), having recovered +36.14% from the 52-week low of ₹697.4. RSI at 64.4 signals neutral momentum (neither overbought nor oversold). Volume trend is increasing, consistent with institutional accumulation.
Ownership flows tell a complementary story: FII ownership rose 1.44 percentage points QoQ to 2.04%, reversing a multi-quarter decline and signalling renewed institutional interest post-result. DII trimmed 1.97pp to 9.84%, while promoters added 1.41pp to 63.31%. The FII inflow is notable—it suggests foreign portfolio managers are viewing the balance-sheet strength (fortress liquidity, disciplined capex, ₹47 Cr buyback + ₹13 Cr dividend) as a de-risking mechanism in a volatile market. Promoter accumulation (now 63.31%) indicates founder confidence; no selling pressure visible near the highs.
The post-result move (day 3 +13.08% and holding) contradicts a bearish reading of flat PAT. The market is not penalizing operational leverage loss; instead, it is pricing: (i) 14-quarter consistency, (ii) infrastructure quality (Plant 6 on schedule), (iii) cash generation and shareholder returns, and (iv) belief that margin recovery is 1–2 quarters ahead (Plant 6 ramp). This is a "trust the balance sheet and the process" trade, not a CDMO-growth momentum bet.
What to watch next
1 · Plant 6 commercialization and first-quarter revenue contribution (Q2 FY27)
Mechanical completion done; validations and customer audits expected to close by end of H1 (Sep 2026, ~6 weeks away). Watch for: announcement of go-live date (±15 days around end Sep 2026), first customer production runs, and depreciation ramp in Q2 P&L. Expect ~₹3 Cr/quarter depreciation impact; success is measured by revenue ramp offsetting this drag within 2–3 quarters.
2 · Trade Generics recovery catalysts and ex-codeine base growth (Q2–Q3 FY27)
TGx has been stagnant ex-codeine for 3–4 quarters. Watch for: (i) new product launches (specific SKU counts and therapeutic areas), (ii) geographic expansion wins (new territories), and (iii) sequential quarter growth (can TGx get back to ₹35–40 Cr run-rate by Q3?). If stagnation persists into Q3, margin recovery thesis weakens materially. Management needs to quantify recovery roadmap, not just invoke 'working on it.'
3 · Organic PAT growth trajectory (Q2 onwards)
Is actual PAT (not ESOP-adjusted) growing sequentially? Plant 6 depreciation starts Q2–Q3, creating near-term headwind. For the margin-recovery thesis to hold, operating profit growth must exceed depreciation drag by Q3–Q4. Watch for: sequential PAT growth >5% (ex-ESOP noise), OPM expansion (toward 11.5%+), and management's ability to reconcile operating leverage loss with topline 18%+ growth narrative. Flat PAT in Q2 would signal structural challenge, not timing.
Windlas Biotech delivered a quarter that looks better on paper (record revenue, 14-quarter streak) than it reads in substance (flat profit, no operating leverage). The ESOP-adjusted PAT claim muddies the transparency; the real number is ₹17.7 Cr, flat YoY. Management's execution on infrastructure (Plant 6 on schedule) and capital discipline (strong buyback + dividend) is credible, but the absence of margin expansion despite 18% revenue growth is a red flag that either (i) fixed-cost deleverage is deeper than expected, or (ii) the TGx loss is wider and more persistent than 'temporary hit' framing suggests.
The stock's day-3 resilience (+13.08%) and FII accumulation reflect market confidence in the balance sheet and Plant 6 catalysts—not in near-term earnings momentum. The debate resolves in Q2 and Q3: can Plant 6 ramp offset depreciation drag, and can TGx stabilize? Until then, this is a Hold for existing holders (balance-sheet quality, Plant 6 de-risks downside) and a Cautious Add for new buyers (wait for Plant 6 commercialization proof and Q2 organic PAT growth). The single number to track from here is actual PAT—not ESOP-adjusted, not claims—Q2 onwards. If it grows mid-single digits and Plant 6 ramps on schedule, the margin thesis holds. If Q2 PAT is flat or negative, the thesis breaks and a repricing is due.
Record revenue, flat profit; Plant 6 catalyst ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Hit Plant 6 timing (H1 FY27), FY26 targets (₹900+ Cr, 19% growth). Claimed 37% PAT growth, but actual PAT flat—ESOP-adjusted claims obscure true earnings.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Windlas delivered 18% revenue growth and 14 consecutive quarters of record volume—solid operational execution. However, actual PAT is flat YoY despite topline strength, signalling margin leverage has stalled. Trade Generics vertical is in freefall post-codeine loss, and management's recovery timeline is vague. Plant 6 commercialization (H1 FY27) is a concrete positive catalyst, but upside is likely priced in. Key risk: Trade Generics stagnation persists longer than expected, delaying margin recovery.
₹248.1 Cr
Revenue · +18.1% YoY₹17.7 Cr
Reported PAT · −0.1% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Highest ever quarterly revenue of ₹248 Cr, 18% YoY growth
METDelivered ₹248.1 Cr, 18.1% YoY — precise match
PAT grew 37% YoY to ₹25 Cr (excluding ESOP)
OVERSTATEDActual delivered PAT ₹17.7 Cr, flat YoY (-0.1%). Claimed ₹25 Cr is pre-ESOP adjustment (₹7.2 Cr); misleading presentation of profit growth.
CDMO vertical delivered 29% YoY growth to ₹207 Cr, highest in long period
METStated ₹207 Cr, 29% growth — corroborates call. However, management temperated this as not necessarily repeatable quarterly.
Plant 6 on track for H1 FY27 commercialization
METMechanical completion done. Validations and customer audits ongoing. End of H1 (Q2 end, ~Sep 2026) targeting achieved per call.
Trade Generics ex-codeine stagnant; acknowledged momentum hit
METTGx + Institutional ₹30 Cr this quarter, down from ~₹85–90 Cr pre-codeine discontinuation. Ex-codeine base at ₹30–35 Cr shows no growth despite management efforts.
Earnings quality
What changed since the last call
TGx momentum broken
DowngradeCodeine-based products (~₹55–60 Cr annually) discontinued. TGx revenue down to ₹30 Cr run rate from ₹85–90 Cr pre-loss. Management acknowledges 'temporary hit' but recovery timeline vague.
CDMO growth inflected upward
UpgradeCDMO 29% YoY growth (₹207 Cr), highest in long period. Driven by customer expansion, deeper engagement, new product launches. However, management cautioned against extrapolation; attributed to business-as-usual execution, not external tailwind.
Injectables now on track
UpgradeAfter slower ramp, injectables 'back on track.' Infrastructure (2 lines + supportive facilities) built; future capacity addition 6–8 months if decided. No new capex announced yet.
Exports accelerating
UpgradeExports 79% YoY growth to ₹11 Cr. Small base, but management calls it 'big opportunity vertical' with high gestation. Focus on geography expansion, portfolio, plant approvals ongoing.
PAT growth claimed but not delivered
DowngradeManagement presented 37% PAT growth (ESOP-adjusted, ₹25 Cr). Actual delivered PAT ₹17.7 Cr flat YoY (-0.1%). No operating leverage despite strong topline.
The Q&A
Analysts pressed hard on TGx stagnation (3–4 quarters flat ex-codeine base, whether recovery to 25–30% growth post-base-effect). Management deflected with focus on long-term value, not quarterly lumps. On CDMO 29% growth, analysts questioned sustainability and API-price benefit; management resisted over-reading single quarter. Strong pushback on capacity addition timing (1.5–2 year lead time risk); management counter-argued disciplined incremental expansion. Generally well-handled; analysts recognized cash flows + balance sheet strength (Sajal Kapoor).
CDMO growth drivers — Dhwanil Desai, Turtle Capital
PartialCDMO grew 29%, highest in long time. Quarterly growth varies due to multiple factors; look at company level, not vertical-wise. Injectables have contributed but not specifically this quarter. No long-term factors have changed.
TGx stagnation — Dhwanil Desai, Turtle Capital
DodgedGrowth is function of product range, geography, execution. We're working on all three. Don't give guidance. Believe sustained efforts will build long-term success.
Plant 6 operational milestones — Sajal Kapoor, Antifragile Wealth
AnsweredPlant 6 similar to Plant 2 expansion. Extend existing portfolio, plant-level approvals by customers, bring in new customers. Success measured in revenue + cash flow.
IPM data & growth correlation — Kumar Saurabh, Scientific Investing
PartialVolume growth is mild even historically. Focus on execution. IPM rebound to 3.4% is welcome sign. Our growth driven by team effort and execution, not tied to IPM.
Capacity utilization & exports — Kumar Saurabh, Scientific Investing
PartialPlant 6 enables ₹1,100 Cr, expandable via debottlenecking to ₹1,250+ Cr. Peak utilization 60–65%, stretchable to 70%. Exports higher gestation; growth 'difficult to say.' Stay positive on opportunity.
TGx ex-codeine growth — Avnish Burman, Vaikarya Investment Management
AnsweredTGx + institutional is lumpy. Codeine removal has impact on momentum. Acknowledge that. Long-term potential remains positive; working on geography, portfolio, alignment.
Employee cost drivers — Avnish Burman, Vaikarya Investment Management
AnsweredMultiple factors: increments, contractual variable manpower (linked to production), Uttarakhand minimum wage increase (retrospective). Volume-driven growth requires more manpower. No extraordinary costs.
Plant 6 depreciation impact — Avnish Burman, Vaikarya Investment Management
AnsweredRoughly ₹30 million/quarter, ±10–15%, initially. Depreciation reduces over time as seen prior quarters.
Working capital trends — Avnish Burman, Vaikarya Investment Management
AnsweredDuring period, inventory and receivables days increased due to geopolitical factors. By end, brought back to similar levels. Overall working capital maintained.
Codeine replacement strategy — Ishit Desai, Fods Family Office
AnsweredIndia's 2 largest cough syrup brands also discontinued codeine. Offered more cough syrups to customers, more liquid products, pack size variants. Portfolio approach, not 1:1 replacement.
Injectables ramp status — Ishit Desai, Fods Family Office
AnsweredYes, now on track per customer feedback and inquiries. If capacity expansion decided, 6–8 months to add machinery, qualify, bring online. Supportive facilities already built. Discussing options.
API price impact on revenue — Vansh Gupta, Prescient Capital
PartialAPI prices volatile. Cost-plus model insulates; customers monitor. Hard to isolate benefit or loss. Focus on supply and output, not margin shaving. Majority of growth volume-linked.
Demand environment changes — Vansh Gupta, Prescient Capital
AnsweredNo specific changes noted. Ability to convert previous work into revenue this quarter in CDMO and Exports. No big strategic movement.
Further capacity roadmap — Resham Jain, VVD Asset Managers
AnsweredUsed some Plant 6 machines in Plant 2 this quarter (contributed revenue). See ₹100–150 Cr more with Plant 6. Focus on debottlenecking existing plants and increasing Plant 6 efficiencies before new capex.
Exports catalysts — Resham Jain, VVD Asset Managers
PartialGeography expansion, portfolio, plant approvals. Lots of registration work, audits ongoing. Timing of conversion varies, but 'big opportunity vertical.'
Gross margin drivers — Avnish Tiwari, Vaikarya Investment Management
AnsweredDriven by business mix, operational efficiencies, CDMO product portfolio converted this quarter, exports growth, value-added products. Maintain material margins customer-level, not quarterly. Fortunate CDMO offset TGx loss.
API price stability outlook — Avnish Tiwari, Vaikarya Investment Management
AnsweredVolatility continues. Inventory increase needed during quarter. Negotiations with customers fast-tracked. No stabilization yet. Very hard to say when stabilization appears.
Brownfield capex timeline — Kumar Saurabh, Scientific Investing
AnsweredIn CDMO, if brownfield oral solids (compliant to new schedule), ~1 year. If new dosage form, different learning curve. Balance: large capacity risks attracting low-margin deals; we prefer disciplined incremental.
Plant 6 commercialization timing — Ankur Kumar, Alpha Capital
AnsweredEnd of Q2 (H1 end, ~Sep 2026). 15 days plus/minus possible. Depreciation starts Q2/Q3 full impact.
Export market expansion — Dhwanil Desai, Turtle Capital
DodgedHave complete visibility of markets and dossiers, but competitive-sensitive. Not sharing details on earnings call.
Facility consolidation strategy — Dhwanil Desai, Turtle Capital
AnsweredNo. Believe incremental expansion better. Large plant risks fixed cost, desperation to fill capacity, loss of control over WC/margins/cash. Incremental discipline preferred. Ensure capacity never hurdle to growth.
New dosage form progress — Dhwanil Desai, Turtle Capital
AnsweredNothing final so far.
CDMO growth base case — Ankur Kumar, Alpha Capital
PartialQuarterly growth not to be base. API portion lower, volume higher, but no huge single matter. Business as usual, quarter where conversion better than usual. No huge change expected.
Guidance
Plant 6 commercialization end H1 FY27; enables ₹1,100 Cr capacity
HighMechanical completion done. Validations and customer audits ongoing. Expected ~Sep 2026.
Debottlenecking potential: ₹100–150 Cr additional revenue from existing plants
MediumManagement believes efficiency initiatives + localized capex can expand revenue ceiling. Mentioned 10–15% expansion possible beyond initial Plant 6 estimate.
No explicit FY27 margin target. Focus on material margins customer-level, not quarterly.
MediumOPM has held ~10–11%. NPM ~7% this quarter. No guidance for margin expansion; PAT flat YoY indicates leverage absent.
Plant 6 commercialization end of H1 FY27. Depreciation ~₹3 Cr/quarter from Q2–Q3.
HighInfrastructure supportive work done. Machinery additions ₹30M depreciation initially, reducing over time.
Maintenance capex ₹12–15 Cr annually. No major new capex projects announced.
HighManagement deliberate on incremental capacity addition, not aggressive greenfield expansion.
Risks the call surfaced
Trade Generics vertical collapse
HighTGx + Institutional fell from ₹85–90 Cr annually to ₹30–35 Cr run rate post-codeine discontinuation. Even ex-codeine base flat 3–4 quarters. Recovery mechanism (new launches, geographic expansion) unproven timeline.
API price volatility
MediumAPI prices remain volatile due to crude-linked geopolitical factors (Middle East crisis). Inventory and receivables days stretched during quarter. Cost-plus model provides some pass-through, but lag and negotiation complexity.
CDMO growth sustainability
MediumCDMO 29% growth is highest in long time, but management explicitly cautioned against reading too much into a single quarter. No major new order book disclosed. Growth sourced from 'business as usual' execution, not external tailwind.
Plant 6 execution and ramp
MediumPlant 6 commercialization end of H1 FY27 (Sep 2026, ~2 months away). Mechanical completion done, but validations and customer audits ongoing. Customer adoption risk; initial utilization may lag. Depreciation drag (₹3 Cr/quarter) to offset revenue ramp.
Injectables adoption lag
LowInjectables 'back on track' after slower start than expected. New dosage form requires customer testing and learning curve. Infrastructure (2 lines + supportive facilities) in place, but conversion of inquiries to orders uncertain.
Management
Score 7/10. Clear on strategy and execution steps (geographic expansion, portfolio, debottlenecking). Evasive on competitive details (export markets, dossier pipelines). Transparent on TGx challenges; not over-claiming recovery timeline. ESOP-adjusted profit figures somewhat obscure actual earnings. Strong 14-quarter track record on revenue growth (targets met). Plant 6 on schedule. TGx recovery unproven (3–4 quarters flat). CDMO execution solid but not exceptional (29% attributed to 'business as usual'). PAT flat despite revenue growth suggests operational leverage absent.
1 · End Q2 FY27 (Sep 2026)
Plant 6 commercialization; mechanical completion done, validations ongoing
2 · Q2–Q3 FY27
Plant 6 depreciation ramp (₹3 Cr/quarter added), margin headwind short-term
3 · FY27–FY28
CDMO customer audits and capacity plant approvals; new customer additions
Key risk: Trade Generics stagnation persists longer than expected, delaying margin recovery.
Windlas standalone Q1FY27: revenue +18% YoY, PAT flat as material costs squeeze margins
PAT -0.06% YoY · revenue +18.09% · margins compressing
₹248.1 Cr
+18.09% YoY
₹17.65 Cr
-0.06% YoY
6.97%
-1.2pp YoY
₹8.46
Windlas Biotech's standalone Q1 FY27 (quarter ended June 30, 2026) revenue rose 18.1% YoY to ₹248.1 Cr from ₹210.1 Cr, continuing the growth trajectory from FY26 (full-year revenue growth of 19%, past ₹900 Cr). Profit after tax, however, was effectively flat YoY at ₹17.65 Cr versus ₹17.66 Cr a year ago (-0.06%), even as it rose 10.4% sequentially from ₹15.99 Cr in Q4 FY26. Basic EPS ticked up marginally to ₹8.46 from ₹8.43 YoY (+0.4%), helped by a lower share count after the ₹47 Cr tender-offer buyback (470,000 shares at ₹1,000) completed in April. No exceptional items appear in either period, so the YoY comparison is clean.
Q1 FY-2027 vs prior quarters
The gap between strong topline growth and stagnant profit is a margin story. Net profit margin (on total income) compressed to 6.97% from 8.20% a year ago, and EBITDA margin fell to 10.75% from 12.63%. Cost of materials consumed jumped to 68.0% of revenue from 59.7% in Q1 FY26, and employee benefit expense rose 37.9% YoY to ₹44.4 Cr (17.9% of revenue versus 15.3%) — both outpacing the 18.1% revenue growth and absorbing the benefit of higher volumes. Sequentially margins improved modestly versus Q4 FY26's 6.58% NPM/10.60% OPM, but the YoY compression is the primary read.
The stock went into the print at ₹823, down 0.8% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Windlas Biotech reported strong FY26 performance with 19% revenue growth, exceeding INR900 crores for the first time. The company is optimistic about future growth, driven by its CDMO and export verticals, with new capacity from Plant 6 expected to commercialize in H1 FY27. Management indicated a focus on strategic inv
Management's prior guidance flagged "operational efficiencies" and capability enrichment as FY27 priorities alongside CDMO/export-led growth and new capacity from Plant 6, expected to commercialize in H1 FY27; this quarter's material and employee cost inflation runs somewhat counter to that efficiency framing, though Plant 6 has yet to contribute. No street consensus estimates for this quarter turned up in a web search and no management press release was available for this filing, so vsStreet is unknown. A structural change also affects future comparability: following the dissolution of non-operating US subsidiary Windlas Inc. effective March 31, 2026, the company has stopped preparing consolidated statements from Q1 FY27 — this quarter's standalone print is the full and only basis, and the impact of the change is likely immaterial since the subsidiary was dormant. Separately, the company paid out ₹130.0 Cr (₹6.30/share) as FY26 dividend on July 31, 2026, per AGM approval.
W1
Whether Plant 6 capacity commercializes as guided in H1 FY27 and its near-term margin impact
W2
Whether the raw material cost ratio (68.0% of revenue in Q1) eases back toward the ~60% seen a year ago
W3
CDMO/export vertical traction, flagged by management as a key FY27 growth driver